Novartis to Pay Voyager $100 Million Upfront for Gene Therapies
XTalks
JANUARY 3, 2024
Novartis and Voyager Therapeutics have struck a licensing deal that will see Novartis pay Voyager $100 million upfront to develop gene therapy candidates targeting Huntington’s disease (HD) and spinal muscular atrophy (SMA). The total value of the deal could potentially reach $1.2 Sandrock, Jr., MD, PhD, CEO of Voyager.
Let's personalize your content